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Abstract
Background: With an increasing number of people with dementia worldwide and limited advancement in medical
treatments, the call for new and cost-effective approaches is crucial. The utility of self-management has been
proven in certain chronic conditions. However, very little work has been undertaken regarding self-management in
people with dementia.
Methods: The SHAPE trial will include 372 people with mild to moderate dementia to evaluate the effectiveness
and cost-effectiveness of an educational programme combining approaches of self-management, health
promotion, and e-learning for care partners. The study is a multi-site, single-randomised, controlled, single-blinded
trial with parallel arms. The intervention arm is compared with treatment as usual. The intervention comprises a 10-
week course delivered as group sessions for the participants with dementia. The sessions are designed to develop
self-management skills and to provide information on the nature of the condition and the development of healthy
behaviours in a supportive learning environment. An e-learning course will be provided for care partners which
covers similar and complementary material to that discussed in the group sessions for the participant with
dementia.
Discussion: This trial will explore the effect of the SHAPE group intervention on people with mild to moderate
dementia in terms of self-efficacy and improvement in key health and mental health outcomes and cost-
effectiveness, along with carer stress and knowledge of dementia.
Trial registration: ClinicalTrials.gov Identifier: NCT04286139, registered prospectively February 26, 2020, https://
clinicaltrials.gov/ct2/show/NCT04286139
Keywords: Self-management, Health promotion, Dementia, Intervention, Group intervention, E-learning, Carers, Self-
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Background
The recent Lancet Commission report on dementia esti-
mated that 47 million people were living with dementia
in 2017 [1]. As the world’s population grows older, this
number is expected to double every 20 years [2]. With
limited advancement in medical treatments combined
with increasing pressures on limited resources, novel
and cost-effective approaches are needed to reduce the
impact of the disease at the individual and societal levels.
More effective self-management is central to achieving
this objective and has the potential to avoid unnecessary
excess disability or premature loss of function and insti-
tutionalisation [3, 4]. There is a growing body of evi-
dence for the health and economic benefits of other
interventions for people with dementia [5] and for their
care partners [6], but so far, little has been done to in-
crease knowledge on the clinical and economic case for
self-management, health promotion and e-learning. A
number of countries have developed national strategies
for dementia and emphasised the importance of provid-
ing disease-related information for the person affected
by the disease and not just for the care partner [7, 8].
Health plans, in countries including Norway [9] and
United Kingdom (UK) [10], are responding to the health
needs of individuals with dementia and their families, as
well as identifying better ways to care for people with
dementia. These policies [11] aim to help citizens stay in
their homes for longer, based in part on an economic
motivation to address the total direct and formal care
cost of dementia, particularly because admission to 24-h
care is expensive [12]. Despite the importance of self-
management, very little work has been undertaken on ei-
ther health promotion or self-management in people
with dementia.
A recent systematic review [13] focused on self-
management for people with dementia and mild cogni-
tive impairment (MCI), and outlined the key compo-
nents of self-management interventions. It found that
while some interventions included some key compo-
nents of self-management, only two studies specifically
reported self-management programmes, and neither of
these presented quantitative outcomes. The SMART
trial, a pilot randomised controlled trial (RCT) [14]
showed quantitative positive findings regarding self-
efficacy, and showed high satisfaction as reported quali-
tatively. Another RCT of self-management [15] also
demonstrated beneficial effects on the health-related
quality of life of spouses and the cognitive function of
persons with dementia. Benefits of self-management in-
clude improved knowledge, task performance, self-
efficacy and aspects of health status [16, 17]. Most em-
pirical work has focused on the self-efficacy component
of this model. Self-efficacy is defined as belief in one’s
ability to succeed or to accomplish a specific action in a
particular situation [18]. The utility of self-management
is long proven for outcomes of other chronic diseases
[19, 20]. We have found that people with early-stage de-
mentia are usually able to identify areas of their lives,
such as exercise, social activities and recreational pur-
suits, which they would like to manage better [21, 22],
which in turn could improve quality of life and well-
being. This offers an avenue for a sensitive and tailored
approach to encourage individuals receiving a diagnosis
of dementia to draw on their resources and on support
from others to make positive changes. Health promotion
includes self-management components such as develop-
ing personal skills; but also covers a wider set of ap-
proaches such as public policy, supportive environments,
community actions and health service perspectives [23].
Evidence exists for the need to assist persons with
early-stage dementia with health promotion to sustain
their function, quality of life, well-being, and prevent
premature loss of function or institutionalisation [24].
Buettner and Fitzsimmons [4] demonstrated significant
positive change in cognition and depression in their
health promotion intervention. The intervention has
been adapted and applied to a Norwegian context [25],
where a quasi-experimental study including 108 persons
with early-stage dementia was conducted. Findings from
this study showed a significant improvement in depres-
sive symptoms and self-rated health in early stage de-
mentia, and participants’ MMSE scores stayed stable
during the 4-month follow-up, which was statistically
significantly different from the average decline in MMSE
scores over the same time period among people with de-
mentia [26, 27]. Furthermore, a similar study by Riche-
son et al. [28] found evidence that health promotion
leads to improved self-efficacy in people with early-stage
dementia. Other studies of health promotion for people
with early-stage dementia have reported improved nutri-
tion, health related quality of life, prevention of falls
[29], and improvement in physical function [30]. A sys-
tematic review by Boots et al. [31] found beneficial ef-
fects of internet-based interventions for care partners of
people with dementia. The review demonstrated im-
provement in various aspects of carer wellbeing, e.g.
confidence, depression and self-efficacy, given that the
programs include multiple components and are tailored
to the individual.
Study objectives
The primary objective is to determine whether the inte-
grated 10-week SHAPE intervention, combining self-
management and health promotion for people with de-
mentia and e-learning for care partners, will significantly
improve self–efficacy in people with mild to moderate
dementia. Secondary objectives are to determine the im-
pact of the SHAPE intervention on mood, well-being,
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quality of life, health behaviours, cognition, neuropsychi-
atric symptoms, carer stress, knowledge of dementia,
and to assess cost-effectiveness in people with dementia
and their care partners. Furthermore, we wish to qualita-
tively explore and describe barriers and promoting fac-
tors for uptake and implementation, and capture
motivational and empowering elements of the interven-
tion and to explore the intervention’s impact on self-
efficacy and wellbeing.
Hypotheses
We hypothesise that the intervention will significantly
improve self-efficacy in people with dementia compared
to treatment as usual. Secondary hypotheses are that the
integrated SHAPE intervention will improve wellbeing
and other key health and mental health outcomes for
people with dementia (e.g. depression, anxiety, health-
promoting behaviour, and quality of life), reduce stress
and increase knowledge of dementia for care partners,
and provide a cost-effective approach to improving out-
comes for people with dementia and their families.
Assessment and management of risk
This is a low-risk, non-pharmacological trial [32]; in
such trials, certain adverse events are not required to be
reported, but should be recorded. Minimal risk of psy-
chological stress may occur as a result of assessments
(e.g. completing a depression scale). Should psycho-
logical distress occur, the research team will provide par-
ticipants with information about local resources that will
assist with their distress.
If a participant is hospitalised during the intervention,
this will be recorded. No deaths are anticipated as a re-
sult of the intervention. However, if a participant dies
during the trial period, follow-up assessments that in-
clude the care partner will be discontinued.
Methods/design
This protocol is reported with reference to the SPIRIT
checklist [33] (Additional file 1).
Overall design
This is a multi-site, controlled, single block-randomised,
single-blinded trial with parallel arms. The intervention
arm is compared with treatment as usual (TAU).
The SHAPE intervention
The SHAPE intervention is based on the Corbin and
Strauss Trajectory Model [34], and combines approaches
of self-management, health promotion, and e-learning.
The intervention is designed to develop self-
management skills in areas including decision-making,
symptom management and social interaction and to
provide information on the disease process and the de-
velopment of healthy behaviours in a supportive learning
environment. The intervention comprises ten weekly 2-h
group sessions for persons with dementia, where each
session is led by two trained facilitators at each study
site. The group facilitators will have professional clinical
training e.g. nursing, occupational therapy, and psych-
ology and have experience of working with people with
dementia. For the care partners involved as study part-
ners, the same material presented in the 10-week
SHAPE course for people with dementia, plus some add-
itional material and signposting to support them in their
role, will be delivered through an online e-learning plat-
form. Key themes of the intervention will include posi-
tive actions to improve and maintain health, how to talk
about the impact of the disease on the life of the person
with dementia, addressing the fear of losing independ-
ence and how to tackle and solve other sensitive issues
(Table 1).
Control arm
Participants randomised to TAU will continue to re-
ceive usual care and support, which may include a
regular nurse-led clinical review and access to services
such as psychiatry, occupational therapy and social
services as needed. Using TAU as a comparator con-
dition ensures that all participants receive needed ser-
vices and allows for a comparison between the new
intervention and current best practice. However, after
the intervention is completed, the TAU group will be
offered the intervention. Furthermore, all participants
in the TAU group will be given the link to the e-
learning comprising the complete educational
programme of the intervention once the trial has
ended. Schedule of enrolment, intervention, and as-
sessments for the SHAPE trial are presented in Fig. 1.
Table 1 Key themes covered in the intervention
Sessions Topic
Session 1 Orientation to the course
Session 2 Healthy lifestyle, doctor’s visits and use of medication
Session 3 Healthy eating, diet and nutrition
Session 4 Staying safe
Session 5 Exercising body and brain
Session 6 Activities, interests and learning
Session 7 Managing memory difficulties
Session 8 Adapting and coping
Session 9 Relationships and communication
Session 10 Planning for the future
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Sample size
The sample size calculation is based on the approach
outlined in Lohr et al. [35] and the aim of detecting a
standardised mean difference of 0.4 in the General
Self-Efficacy Scale (GSES) between the intervention
and control arms of the trial, with 90% power at the
5% significance level. An effect size (Cohen’s D) of
0.4 is a commonly used threshold for clinical mean-
ingfulness [36]. A standard sample size calculation
suggests that 268 participants would be required (134
participants per arm). Including in the analysis covari-
ates that are predictive of the outcome will increase
Fig. 1 Standard protocol items recommendations for intervention trials (SPIRIT): Schedule of enrolment, intervention, and assessments for the
SHAPE trial
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the precision of the effect estimate and hence the
statistical power. Assuming a coefficient of determin-
ation R2 of 0.25 for the regression of the outcome on
baseline variables, the required total sample size is re-
duced to 201 [37].
Due to the potential for a clustering effect in the inter-
vention because participants are attending group ses-
sions where the outcomes for individuals nested within
the same educational groups [WS8] are likely to be more
similar than the outcomes for individuals within differ-
ent groups, the variance in the intervention arm will be
inflated. We assume a residual intra-cluster correlation
coefficient (ICC) of 0.1. We plan for group sizes of 8 in
the intervention arm and an allocation ratio of 2:1 (i.e.
67% of participants will be allocated to the treatment
arm). Assuming 25% attrition we anticipate an average
number of 6 participants within each cluster contribut-
ing data for analysis. Given this plan, and allowing for
attrition, we will need to recruit a total of 246 partici-
pants to the intervention arm and 123 participants to
the TAU arm in order to provide sufficient power for
the primary analysis. Harmonising to a fixed block size
we will recruit 248 participants to the treatment arm
and 124 participants to the control arm, i.e. a total of
372 participants. Additional allowance for varying group
sizes is not necessary if the coefficient of variation in
cluster sizes is smaller than 0.23 [38], which we expect
to be the case in this study design.
Recruiting centres
Stavanger University Hospital (SUH) and Norwegian Na-
tional Advisory Unit on Ageing and Health in Norway
(AH), the University of Exeter and partner National
Health Service (NHS) Trust(s) in the UK, the University
of New South Wales with Prince of Wales Hospital
(UNSW) and Dementia Australia as partners will all act
as recruiting centres.
Planned recruitment rate
Across all four sites combined, we will recruit a total of
372 participants to the study. The recruitment will hap-
pen in blocks of 12 participants at each site, of which 8
will be randomised to the SHAPE intervention and 4 to
TAU. The planned distribution among the centres is 84
participants at Exeter, 96 at A&H, 108 at SUH and 84 at
UNSW.
Month 1 will be spent recruiting the first blocks of
participants, who will have their baseline visits in the
first 2 weeks of month 2, with a maximum of 2 baseline
interviews per day at each centre. Following this we will
randomise consenting participants, and inform them of
their allocation and for those in the intervention arm the
start date of the course. Start-up of the first course
groups will be in month 3. Further recruitment will
happen concurrently, and we anticipate that we will have
enough participants to start up at least one new course
group at each centre every 1.5 months, meaning that re-
cruitment will be completed in 13 months, and the last
course groups will start in month 15.
Randomisation
When recruitment reaches a group target of 12 con-
sented pairs of participant and carer partners at a site
we will proceed to randomisation. A computer-
generated randomisation sequence will be used to assign
the participant pairs in each site to the intervention and
control arms. A block randomisation scheme will be im-
plemented to ensure an appropriate ratio in the number
of participant pairs allocated to each trial arm, stratified
by group delivery site. The allocation sequence will be
concealed from researchers (outcome assessors) using an
online central randomisation service set up and main-
tained by the Exeter Clinical Trials Unit (UKCRC Regis-
tration ID 65). Group facilitators and pairs of participant
and care partners will not be blinded.
The participants and their care partners will receive an
email and letter indicating the result of randomisation.
Participants allocated to the intervention arm will be
sent details of the group sessions and will be contacted
by their Lead Facilitator before the first group session,
and their care partner will receive a link to the online e-
learning platform.
Blinding
Quantitative data will be collected by a researcher blind
to the participants’ allocation (intervention vs TAU).
Outcome and study eligibility measures
All quantitative outcome measures will be assessed prior
to randomisation (baseline), after the intervention (fol-
low-up 1) and then 6months after follow-up 1 (follow-
up 2). The assessments will consist of questionnaires
using standardised, evidence-based scales and other in-
formation obtained from the participant and appointed
care partner. The interviews will be conducted with the
participant and care partner, both together and separ-
ately. Participant and care partner demographic details
will be collected.
The primary outcome in the SHAPE trial is self-
efficacy measured by the General Self-Efficacy Scale
(GSES) [39]. The secondary outcome measures in-
clude cognition assessed with the Mini Mental State
Examination (MMSE) [40], which is also used to
check eligibility, depressive symptoms measured by
the Cornell Scale for Depression in Dementia (CSDD)
[41], quality of life and well-being measured by the
Dementia Quality of Life Scale (DEMQOL) [42],
health-related quality of life measured by EQ-5D-5L
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[43], neuropsychiatric symptoms measured by the
Neuropsychiatric Inventory Questionnaire (NPI-Q)
[44], health behaviour changes measured by the
SHAPE research team health reporting form, use
of support services measured by the Client Services
Receipt Inventory (CSRI) [45], carer stress measured
by the Relative‘s Stress Scale (RSS) [48], carer sense
of competence measured by the Short Sense of Com-
petence Questionnaire (SSCQ) Short version [49], and
knowledge about dementia measured by the Dementia
Knowledge Assessment Scale (DKAS) [50]. We will
use the Clinical Dementia Rating Scale (CDR) [39] to
measure level of dementia and to measure functional
changes in the participants we will use the Functional
Activities Questionnaire (FAQ) [40]. A full description
of the primary and secondary outcomes and screening
instruments is provided in Table 2.
Economic evaluation
For the economic evaluation, there will be two co-
primary outcomes: self-efficacy (GSES) [39] and QALY
gain (calculated from EQ-5D-5L self-report; societal
weights) [43]. Secondary outcomes will be QALY gain
from DEMQOL self-report [51], care partners’ QALY
gain (calculated from carer-reported EQ-5D-5L), CSDD
[41], and carer stress (RSS) [46]. Two perspectives will
be employed: health and social care system, and societal
(including costs of unpaid care).
Costs of the self-management intervention (e.g. staff
costs, room hire and materials) will be collected on pro-
formas devised for the study; costs of the e-learning
course for care partners will be collected from the pro-
ject team. We will calculate incremental cost-
effectiveness ratios (ICER) as the difference in costs be-
tween SHAPE and TAU (either service-related or soci-
etal, depending on perspective) over the difference in
outcomes between groups, for each outcome in turn.
Service-related costs will be based on (i) participant-
with-dementia service costs; and (ii) costs of participants’
and care partners’ service use. In addition, an ICER will
be calculated from participant-plus-carer costs and com-
bined participant and care partner QALY (calculated
from EQ-5D). Cost-effectiveness analyses will be con-
ducted using a combination of bootstrap sampling and
cost and outcome regressions taking into account clus-
tering, correlations between costs and outcomes, and
skewed dependent variables. Regressions will include
treatment allocation; baseline scores of the dependent
variable (e.g. utility, GSES, costs and other baseline vari-
ables as relevant). Sensitivity analyses will explore impact
on findings of changes in key cost and outcome assump-
tions. We will calculate net monetary benefit and con-
struct cost-effectiveness acceptability curves to explore
the likelihood of cost-effectiveness over a range of
willingness-to-pay values, taking into account decision
and sampling uncertainty [52, 53].
Qualitative evaluation
Qualitative outcome will be obtained during the inter-
vention and immediately after group completion, using
direct observations of participants and focus groups with
group facilitators. The qualitative evaluation is designed
to develop a deeper understanding of and insight into
the intervention to i) provide recommendations for fu-
ture work and ii) explore the impact of the intervention
on self-efficacy and wellbeing.
Group observations
To study the process of engagement in the group ses-
sions, we will observe 5 groups (3 in Norway, 1 in UK
and 1 in AU), each consisting of up to 8 participants
(n = 40) over the duration of the course (10 weeks). We
will use a moderate participant observation method,
where the researchers are present and identifiable, with-
out engaging in any form of interaction with the partici-
pants [54]. The observations will be carried out on study
commencement, by an observation team with a mini-
mum of two researchers with different backgrounds. We
will develop an observational protocol that includes a
range of pre-selected topics, including (1) in-session be-
haviour, (2) participant engagement, (3) social inter-
action within the group, (4) peer support and (5) change
in perceptions of living with dementia. The field notes
will be transferred to word documents for analysis.
Focus groups
To identify promoting and hindering factors affecting
the SHAPE intervention, focus groups involving the
group facilitators (n = 4–8) will be conducted in all sites
(n = 5, i.e. 3 in Norway, 1 in UK and 1 in AU). The focus
groups will be led by an experienced researcher (moder-
ator), and a co- moderator will make notes on observa-
tions and impressions during the focus group
discussions. A semi-structured topic guide, which will be
revised iteratively allowing the main issues identified by
participants to be explored in depth, will guide the dis-
cussions (see Additional file 1). The focus groups will be
recorded and transcribed verbatim; observations and im-
pressions will be noted at the end of each group.
Intervention fidelity
To monitor intervention fidelity, group facilitators will
complete checklists of topics covered in each session
and outline any deviations from the session plans. Par-
ticipants’ attendance at the sessions will be recorded. If
participants do not meet up for a session, the group fa-
cilitators will follow-up with a phone call.
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Table 2 Description of measures
Measures What does the
tool measure
Informant Tool characteristics and psychometric properties
CDR [49] Diagnostic criteria Care partner Assesses six domains of cognitive and functional performance: memory,
orientation, judgment & problem solving, community affairs, home & hobbies, and
personal care. 0 = no cognitive impairment, 0.5 = questionable or very mild
dementia, 1, 2 and 3 for mild, moderate and severe dementia. Scores in each of




Care partner 10-item scale measuring instrumental activities of daily living. The score range for
each item is 0–3, with higher scores indicate greater impairment; 0 = normal or
never did but could do now; 1 = has difficulty but does by self or never did but
would have difficulty now; 2 = requires assistance; 3 = dependent.
MMSE [40] Cognition Participant 30-point questionnaire, with items assessing orientation, attention, immediate and
short-term recall, language, and the ability to follow simple verbal and written
commands. Lower scores indicating more severe cognitive problems.
GSES [39] Self-efficacy
Primary outcome
Participant 10-item psychometric scale designed to assess a person’s sense of competence for
dealing effectively with a variety of stressful situations. Responses are rated on a 4-






Based on impressions from interviews with the person with dementia and their
care partner, the final ratings of the CSDD items represent the rater’s clinical
impression rather than the responses of the care partner or the person with
dementia. The scale consists of 19 items that ranges from 0 (absent) to 2 (severe).
Total score ranges from 0 to 38, with higher values indicating more depressive
symptoms.




The measure consists of two questionnaires. DEMQOL, conducted with person with
dementia is a 28-item interviewer- administered questionnaire with the score range
of 28 to 112. DEMQOL-Proxy is a 31-item interviewer-administered questionnaire
answered by a care partner with a score range of 31 to 124. The DEMQOL-Proxy is





Participant and their care partner indicate the participant’s health state across five
dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depres-
sion. Each dimension has 5 levels: no problems, slight problems, moderate prob-
lems, severe problems and extreme problems. Additionally, the participant’s self-
rated health is measured on a vertical, visual analogue scale, where 0 represents
‘worst imaginable health state’ and 100 represents ‘best imaginable health state’.
NPI-Q [44] Neuropsychiatric
symptoms
Care partner 12-item questionnaire developed to assess behavioural disturbances in people with
dementia. NPI-Q is a validated structured interview assessment with a care partner.
Scores are entered for the frequency and severity of each symptom over the last
four weeks, and subsequently multiplied into a symptom score. The total possible








The SHAPE research team will create a health reporting form based on the SHAPE
intervention that asks about specific health-related change that occurred during
each time period. Data from self- and family report.




Used to estimate the cost of the participant’s service package and of support
services for the care partner. Information collected: participant’s use of hospital,
community-based and day services, participant’s mental health medications, care
partner’s use of support services and mental health medications. Questions cover a
retrospective period of 3 months.
RSS [46] Carer stress Care partner 15-item, 5-scale self-report measure designed to assess the degree of distress and
social upset experienced by a relative as the result of caring for a person with phys-
ical and/or behavioural difficulties.
SSCQ [47] Carer sense of
competence
Care partner 7-item questionnaire covering 3 domains: consequences of involvement in care for
the personal life of the care partner, satisfaction with one’s own performance as a
care partner, and satisfaction with the person with dementia as a recipient of care.
DKAS [48] Knowledge about
dementia
Care partner 25-item scale measuring dementia knowledge across four domains: causes and
characteristics, communication and behaviour, care considerations, and risks and
health promotion.
CDR: Clinical Dementia Rating Scale, FAQ: Functional Activities Questionnaire, MMSE: Mini Mental State Examination, GSES: General Self-Efficacy Scale, CSDD:
Cornell Scale for Depression in Dementia, DEMQOL: Dementia Quality of Life Scale, NPI-Q: Neuropsychiatric Inventory Questionnaire, CSRI: Client Service Receipt
Inventory: RSS: Relative‘s Stress Scale, SSCQ: Short Sense of Competence Questionnaire, DKAS: Dementia Knowledge Assessment Scale
Testad et al. BMC Public Health         (2020) 20:1508 Page 7 of 13
Participant selection: inclusion, exclusion and withdrawal
criteria
Inclusion criteria
 Diagnosis of dementia according to the ICD-10 clas-
sification [55] or the Diagnostic and Statistical Man-
ual of Mental Disorders (DSM) IV or V [56]
 65 years of age or older
 Mild to moderate dementia, defined as MMSE ≥18
 Ability to read and write
 Hearing and vision that are sufficiently good to work
in a group setting
 Capacity to give consent for participation in the
study
 Proficient in the language in which the intervention
is provided
 Care partner willing to participate
Exclusion criteria
 A diagnosis of alcohol or drug abuse
 Lewy body dementia, Fronto-temporal lobar degen-
eration or Semantic dementia
 A limited life expectancy due to any terminal disease
or other serious illness, other than dementia
 Chemotherapy or radiation treatment ongoing at
enrolment
 Currently participating in another health promotion
or self-management group
Withdrawal criteria
Individual participants can withdraw from the study at
any time, without giving a reason.
Enrolment procedure
Details of enrolment, how the participants will be in-
formed whether they have been allocated into the inter-
vention or TAU, and enrolment in the e-learning
program are shown in Fig. 2. Information will be given
to primary care services, including general practitioners
(GP) offices; memory clinics, user organisations and so-
cial media through flyers in the areas of the individual
study sites.
Safety reports of serious adverse events (SAE)
Fatal and life-threatening events (otherwise known as
Serious Adverse Events) experienced by participants
while participating in the study are unlikely to be
caused by participation in this trial; however, they will
be recorded. SAE reporting will be done according to
the requirements of the National Research Ethics Ser-
vice (NRES) in each individual country. The site PI
will inform trial managers and the sponsor of local
procedures and ensure that these are followed at each
site. SAEs will also be reported to the sponsor and
Independent Data Monitoring Committee (IDMC)
every 6 months, unless more frequent reporting is re-
quested. PIs will also ensure that AEs are recorded,
but there is no requirement to report these to the
sponsor or regulatory bodies unless requested.
The IDMC will consist of an independent statistician
(Chair), a consumer/user representative and a re-
searcher. There will also be a trial representative on the
committee. The IDMC will meet every 6 months and if
necessary in response to any serious untoward incidents.
The IDMC will be responsible for monitoring serious
adverse effects, protocol violations and any risks emer-
ging from the trial.
Data management and analysis
It is planned that anonymous data and all appropriate
documentation will be kept securely for the defined
period required from the relevant ethics committees.
Participants will be clearly informed that their data will
be used for the stated purposes of the study. Only mem-
bers of the study team and its support staff will see the
data. A full clinical Data Management Plan will be writ-
ten by the trial team before recruitment commences,
which will include a privacy impact assessment. All
paper-based data will be double entered. Data will be en-
tered into a secure Electronic Data Capture System
(EDC). This database is built to validated standards and
maintained and managed by the UKCRC registered Exe-
ter Clinical Trial Unit.
Data from questionnaires will be anonymised through
the use of unique participant identification codes when
entered into computers for statistical analysis.
Qualitative data from the interviews will be transcribed
verbatim and then anonymised through the removal of
people’s names and other personal information; where
necessary non-identifiable terms or pseudonyms will be
used instead. In reports of the work, where excerpts are
quoted from interviews, any information that might lead
to the identity of participants, other people or organisa-
tions being inferred will be disguised.
All data will be collected and stored in accordance
with data protection regulations in the individual
countries. Data will be stored electronically on com-
puters and access will be controlled via passwords
and permissions to dedicated study folders. Hard cop-
ies of questionnaires will be securely stored in locked
filing cabinets in offices that are accessible only to re-
search staff. Information used in the administration of
the study, including participants’ names and ad-
dresses, will be stored separately from the research
data and used only to maintain contact with
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participants. Administrative databases will be held at
the study centres.
The CI will preserve the confidentiality of participants
taking part in the study and is registered under the EU
GDPR (General Data Protection Regulation (Regulation
(EU) 2016/679)). The research will follow GDPR
guidance. Only members of the research team will have
access to the original data, which will be stored in a
locked filing cabinet. Participants’ personal details will
be stored separately from the original data, and will be
kept in a separate file on a password protected computer
at the study sites. Access to data will be limited to
Fig. 2 Enrolment process
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quality control, audit, and analyses. Data shared between
sponsor and co-investigators will be de-identified to
minimise breach of confidentiality. Each participant will
be assigned an identification code, which will be used in
all data storage files; these will not contain names or any
other means of personal identification. All personal de-
tails will be deleted on completion of the study.
Statistical analysis
All outcome measures will be reported at baseline,
after the intervention (follow up 1) and at 6-months
after follow-up 1 (follow up 2). Baseline characteris-
tics (age, gender, ethnicity, civil status, education, liv-
ing situation, use of medication) will be presented for
each intervention group and by site. Trial analysis will
include all participants with allocation to study arms
as randomised, i.e. on an intention-to-treat basis.
The primary outcome measure (GSES) [39] will be
analysed using the multilevel modelling approach to
analysis of covariance (ANCOVA), i.e. with follow-up
GSES as dependent variable and with study arm, site
Norway 1, Norway 2, UK and Australia, baseline
GSES, time since baseline assessment, other baseline
variables predictive of the outcome, as well as poten-
tial variables constituting baseline imbalance between
study arms, as independent variables, while allowing
for clustering within treatment groups [57]. The esti-
mate of the effect of the intervention will be re-
ported with a 95% confidence interval and associated
p-value. Missing outcome data will be handled by in-
cluding any variables predictive of missingness in a
complete case-analysis of the multilevel ANCOVA
model [58]. The estimate of the effect of the inter-
vention will be reported with a 95% confidence
interval and associated p-value. Secondary outcomes
will be analysed similarly.
Multiple imputation (MICE) will be used for sensitivity
analysis to assess the robustness of the results to differ-
ential loss to follow up [58].
Qualitative analysis
Qualitative data will be analysed by way of systematic
text condensation [59]. This approach involves the
following steps in the analysis process: (1) establishing
an overall impression of the data material and identi-
fying preliminary themes by reading through the tran-
scripts several times; (2) identifying and sorting units
of meaning into code groups; (3) condensing the con-
tents of each of the coded groups into subgroups;
and (4) summarising and re-contextualising the con-
tents of each code group to generalise descriptions
and concepts. Malterud [59] argues that the data ana-
lysis will benefit from being conducted by more than
one researcher; thus all transcripts will be read by
several members of the research team to get an over-
all impression of the full data material, as in step (1)
above. This step of the analysis requires the re-
searcher to read with an open mind from a bird’s-eye
perspective all pages within the transcripts, and then
ask which preliminary themes (usually four to eight
themes) can be identified in the material.
User involvement
People with dementia, care partners and group facili-
tators from earlier health promotion groups [25] will
be involved in all levels and all phases of the study
including research planning, delivery and dissemin-
ation, and there will be extensive use of co-design
groups and close collaboration with organisations
representing people with dementia. This will ensure
that the development and delivery of the integrated
intervention for people with dementia and their fam-
ilies is centred around the needs of people with de-
mentia themselves in all of the participating
countries. Each site will appoint a user representative
as a member of the respective research teams. This
will ensure that perspectives from people with demen-
tia, care partners and group facilitators from earlier
health promotion groups are included and addressed
throughout the trial.
Study management
This study will be managed by the chief investigator
(Ingelin Testad), the trial manager (Martha Therese
Gjestsen) and the Programme Management Group
(PMG), as part of the overall SHAPE programme.
The PMG will be chaired by Lynne Quinn, Clinical
Trial Unit, Exeter University and involve all the PIs,
the trial manager and a consumer representative. The
group will meet at 3 monthly intervals and addition-
ally as required. Part of the remit of the PMG will be
to oversee overall progress of the programme and
monitor progress against milestones. Any discrepancy
from milestones will be highlighted and a plan, devel-
oped to address the difficulties, will be instigated. For
the purposes of this trial, the PMG will be acting as
the Trial Management Group (TMG), with direct
oversight of and responsibility for this study. The trial
manager will send a written report to the chair of the
PMG before each TMG meeting, detailing progress.
The day-to-day management of the trial will be con-
ducted by the trial manager, Martha Gjestsen, who will
be supervised (weekly) and line managed by Ingelin Tes-
tad. Additional supervision will be organised as needed,
and major decisions will be discussed with PI group and
PGM group, as appropriate.
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Indemnity
Each participating site will be responsible for providing
indemnity to meet the potential legal liability of investi-
gators/collaborators arising from harm to participants in
the conduct of the research. No provision is made for
non-negligent liability, which will be covered by usual
procedures by the care provider as applicable.
Study sponsor
This study is sponsored by Stavanger University Hospital
(SUH), Armauer Hansens vei 2, 4011 Stavanger, Norway.
Telephone: + 47 51 51 98 28, svein.skeie@sus.no
Publication and dissemination strategy
The study’s Dissemination and Publication Policy will
be developed by the trial team and approved by the
PMG as part of the Publication strategy for the whole
SHAPE programme. To ensure authorship eligibility
the Vancouver recommendations will be used. Scien-
tific outputs, the use of the networking opportunities
afforded by each country and making direct contact
with local Commissioners will all ensure dissemin-
ation. A full and open publication of the results will
be provided through peer-reviewed scientific journals.
Additional communication will be undertaken through
the web pages of the EU JPND, Stavanger University
Hospital, Ageing and health, University of Exeter, Alz-
heimer’s Society and University of New South Wales.
Discussion
The integrated SHAPE intervention represents a novel
and different approach combining self-management
and health promotion for people with dementia and
e-learning for care partners. It is based on health pro-
motion and self-management and on the imperative
to maintain the dignity and autonomy of the person
with dementia and support him or her in planning
for the future together with the family. The adjunct-
ive e-learning platform will provide care partners with
the same information that the person with dementia
receives plus some additional material and signposting
to support them in their role. This will further em-
power the whole family to support and enable more
effective self-management by the person with demen-
tia, and enhance their ability to plan ahead together
and make key decisions jointly - such as how and
when to communicate their needs to health care ser-
vices and to receive appropriate care at the right
time. Being able to talk openly about the disease
process and future challenges with family members in
the early stage of the disease can be empowering for
everyone involved. The website with the e-learning re-
sources provided to the care partners will collect
information on website use. The e-learning compo-
nent will also be created in a version which does not
collect any data on the user. The purpose of this is
so it can be distributed to other people in the sup-
port network of the person with dementia, and it
therefore has the potential to reach those who live in
regional, rural and remote areas.
Trial status
At the time of submission of this protocol paper (proto-
col version 6, dated 10.03.2020) was not open to recruit-
ment. Recruitment is scheduled to start in November
2020, providing the COVID-19 pandemic situation al-
lows this, and to be completed by January 2022.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12889-020-09590-9.
Additional file 1. THEMATIC FOCUS GROUP INTERVIEW GUIDE.
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